Big Solana investment has this little fellow soaring

In partnership with

& The Steady Trader

Good day, 360!

Special invite to join Jeff Williams & his special guest - overbought/oversold PRO - on their mission to conquer the current market turmoil. TODAY in Market Masters at 11AM EST🔥. Be the best prepared trader on the Street!

FOCUS LIST🔎

KIDZ - Up over 50% in the pre-market after announcing $400 million equity purchase facility agreement to launch SOL-based treasury strategy

AIRS - Up over 15% in pre after reporting earnings 

ADIL - Up over 18% in pre announcing expansion of intellectual property portfolio with new U.S. patent granted for genetic-based treatment of alcohol and opioid use disorders

HOTLIST🔥

KIDZ - Up over 50% in the pre-market after announcing $400 million equity purchase facility agreement to launch SOL-based treasury strategy

Classover Holdings Inc. (KIDZ) operates as an education technology company that provides online interactive live courses for K-12 students in the United States and internationally.

Yesterday, the company announced  that it has entered into an Equity Purchase Facility Agreement with Solana Strategies Holdings LLC providing for the sale by the Company of up to $400 million of Class B Common Stock. 

Proceeds from the facility will be used to support the Company's Solana-centric digital asset treasury strategy as well as for working capital and strategic acquisitions. 

Under this initiative, Classover will, subject to certain limitations, allocate a significant portion of the proceeds received from the sale of any shares under the facility to the purchasing, long-term holding, and staking of Solana ("SOL") tokens - positioning itself among the first publicly traded companies to integrate SOL directly into its core treasury operations. In addition, the Company plans to operate SOL validator nodes to contribute to the network's decentralization and security while generating on-chain staking rewards.

After closing up over 360% yesterday, shares of KIDZ traded up over 50% in the pre-market in reaction to the news.

The $7.70 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $9, $10 and then the pre-market high at $10.29. Beyond that, $11.50, $11.90 and new all-time highs come into play.

Below $7.70, targets to the downside are $7, $6, $5, $4, $3 and $2 come into play.

AIRS - Up over 15% in pre after reporting earnings 

AirSculpt Technologies Inc. (AIRS) together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom.

In the pre-market this morning, the company announced results for the first quarter ended March 31, 2025.

Highlights Include:

First Quarter 2025 Results

Case volume was 3,076 for the first quarter of 2025, representing a 17.9% decline from the fiscal year 2024 first quarter case volume of 3,746;

Revenue declined 17.3% to $39.4 million from $47.6 million in the fiscal year 2024 first quarter;

Net loss for the quarter was $2.8 million compared to net income of $6.0 million in the fiscal year 2024 first quarter; and

Adjusted EBITDA was $3.8 million compared to $7.3 million for the fiscal year 2024 first quarter.

2025 Outlook

The Company projects full year 2025 revenue and adjusted EBITDA guidance as follows:

Revenues of approximately $160 to $170 million

Adjusted EBITDA of approximately $16 to $18 million

Shares of AIRS traded up over 15% in the pre-market in reaction to the news.

The $2.47 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.64, $2.90 and then the pre-market high at $3.32. Beyond that, $3.90 and $4.50 come into play.

Below $2.47, targets to the downside are a gap fill at $2.26 and then $2.

ADIL - Up over 18% in pre announcing expansion of intellectual property portfolio with new U.S. patent granted for genetic-based treatment of alcohol and opioid use disorders

Adial Pharmaceuticals Inc. (ADIL) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

Yesterday, the company announced patent number 12,274,692 was issued on April 15, 2025 by the United States Patent and Trademark Office (USPTO) covering a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients.

After closing yesterday up over 13%, shares of ADIL traded up over 18% in the pre-market this morning.

The $0.85 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $1, $1.10, $1.17 and then the after-hours high at $1.23. Beyond that, $1.30, $1.50 and $1.80 come into play.

Below $0.85, targets to the downside are a gap fill at $0.78 and then $0.65.

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed 🚀past the MOON 🌝.  Text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.